Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALVR 106

Next Previous
Search
Drug Profile

ALVR 106

Alternative Names: ALVR-106

Latest Information Update: 02 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer Kalaris Therapeutics
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Suspended Influenza virus infections; Metapneumovirus infections; Parainfluenza virus infections; Respiratory syncytial virus infections

Most Recent Events

  • 18 Mar 2025 AlloVir has merged with Kalaris Therapeutics to form Kalaris Therapeutics
  • 07 May 2024 Suspended - Phase-I/II for Parainfluenza virus infections (In adolescents, In the elderly, In adults) in USA (Parenteral)
  • 31 Jan 2024 AlloVir terminates a Phase-I/II clinical trial in Influenza virus infections (In adolescents, In adults, In the elderly) in USA (Parenteral) due to strategic business decisions (NCT04933968)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top